Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase

Abstract

Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include inhibitors or antagonists of leukotriene A4 hydrolase (“LTA4H”) with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.

1 . A method of improving cognitive function in a subject diagnosed with a dementia disorder, the method comprising administering a therapeutically effective amount of an LTA4H modulatory agent. 
     
     
         2 . The method of  claim 1  wherein the dementia disorder is selected from the group consisting of vascular dementia and dementia with Lewy bodies. 
     
     
         3 . The method of  claim 1  wherein the LTA4H modulatory agent is a small organic molecule antagonist to LTA4H. 
     
     
         4 . The method of  claim 1  wherein the LTA4H modulatory agent is an antibody to LTA4H. 
     
     
         5 . The method of  claim 3  wherein the antagonist to LTA4H antagonizes the epoxide hydrolase activity of LTA4H. 
     
     
         6 . The method of  claim 3  wherein the antagonist to LTA4H antagonizes both the epoxide hydrolase activity and the aminopeptidase activity of LTA4H. 
     
     
         7 . The method of  claim 1  wherein the subject is a mammal. 
     
     
         8 . The method of  claim 7  wherein the mammal is a human. 
     
     
         9 . A kit for use in improving cognitive function in a subject diagnosed with an age-related cognitive disease, the kit comprising an LTA4H modulatory agent. 
     
     
         10 . The kit of  claim 9  wherein the LTA4H modulatory agent is a small organic molecule antagonist to LTA4H. 
     
     
         11 . The kit of  claim 9  wherein the LTA4H modulatory agent is an antibody to LTA4H. 
     
     
         12 . The kit of  claim 11  wherein the antagonist to LTA4H antagonizes the epoxide hydrolase activity of LTA4H. 
     
     
         13 . The kit of  claim 12  wherein the antagonist to LTA4H antagonizes both the epoxide hydrolase activity and the aminopeptidase activity of LTA4H. 
     
     
         14 . The method of  claim 1  wherein the dementia disorder is vascular dementia. 
     
     
         15 . The method of  claim 1  wherein the dementia disorder is dementia with Lewy bodies.